semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Parkinson's Disease Either gender, no age or location restriction Diagnosed with idiopathic Parkinson's disease by a Neurologist Able to stand 2 minutes, unassisted Able to walk 10 meters, unassisted Able to understand English instructions  A neurological disease other than Parkinson's disease Peripheral neuropathy Clinically diagnosed with dementia
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-69.0,  Prostate Cancer Prostate Biopsy Genetic Counselling Genetic Markers Men with either: 1. A positive family history of PrCa defined as Men with a first degree relative (or second degree if through female line) with histologically or death certificate proven PrCa diagnosed at <70 years Men with two relatives on the same side of the family with histologically or death certificate proven PrCa where at least one is diagnosed at <70 years Men with three relatives on the same side of the family with histologically or death certificate proven PrCa diagnosed at any age 2. Of African or Caribbean ancestry defined as: Both parents and all 4 grandparents from that origin Age 40 years WHO performance status 02 (see Appendix A) Absence of any psychological, familial, sociological or geographical situation potentially hampering compliance with the study protocol and follow up schedule  Previous cancer with a life expectancy of less than five years Previous PrCa Negative biopsy within one year before recruitment Comorbidities making prostate biopsy risk unacceptable (Warfarin or Clopidogrel) Contraindications to having an MRI (pacemakers, aneurysm clips, claustrophobia)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hypertension Diabetes Mellitus, Type 2 Formal diagnosis of Type II Diabetes Mellitus, Stage I or II Hypertension or both Daily medications required for patient's condition Residence and receipt of therapy within the study catchment area Age greater than or equal to 18 years  Known or suspected secondary hypertension Known or suspected Type 1 diabetes Pregnancy Chronic use of glucocorticoids
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 45.0-75.0,  Parkinson's Disease PD patients with bilateral STN DBS placement and FOG at 130Hz even at usual medication "on" state  Known history of recent aspiration pneumonia
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Idiopathic Parkinson's Disease Subjects must have a clinical diagnosis of idiopathic Parkinson's disease and presence of at least 2 out of 3 cardinal characteristics (tremor, rigidity and/or bradykinesia) Must be Hoehn & Yahr Stage II-III inclusive and experiencing motor fluctuations in the form of end-of-dose wearing off during the morning hours or early morning akinesia Subjects should be able to recognize their "wearing off" symptoms and verify that they usually improve after their next dose of Parkinson's disease medication. Subjects should be able to recognize drug-induced dyskinesias and verify whether or not they are troublesome  History or clinical features consistent with an atypical parkinsonian syndrome, (for example: ataxia, dystonia, clinically significant orthostatic hypotension
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Parkinson's Disease (PD subjects) Male or female age 40 or older at the time of PD diagnosis Clinical diagnosis of PD based on bradykinesia plus one of the following: rest tremor or rigidity DAT deficit at screening based on visual interpretation of DaTSCAN™ imaging PD subjects will need to fall into one of the following stages Early untreated PD not requiring dopamine replacement medication (anticholinergics, MAO-B inhibitors and amantadine permitted), Hoehn and Yahr 1-2, < 2 years from diagnosis Moderate PD responsive and currently treated with dopamine replacement therapy without evidence of motor fluctuations or dyskinesias Advanced PD with motor fluctuations or dyskinesias, > 5 years from diagnosis Ability to provide written informed consent in accordance with Good Clinical Practice (GCP), International Conference on Harmonization (ICH), and local regulations Willing and able to comply with scheduled visits, required study procedures and laboratory tests. (HC subjects)  (all subjects) Has a history of cancer (other than basal and squamous cell skin cancers), autoimmune disorder, liver disease, or other hematological disorder within the past 5 years Current treatment with anticoagulants (e.g., Coumadin, heparin) that would preclude safe completion of the lumbar puncture (LP) and tissue biopsy procedures Current treatment with an antiplatelet agent (Plavix or aspirin >325 mg/day) Has a diagnosis of diabetes mellitus requiring either an oral agent or insulin therapy A bleeding diathesis, or clinically significant coagulopathy or thrombocytopenia Has received botulinum toxin injections to the submandibular gland within the past year Has a condition that precludes safe performance of routine LP, such as prohibitive lumbar spinal disease Has a condition that precludes the safe performance of the flexible sigmoidoscopy procedure or may interfere with obtaining evaluable colonic tissue biopsies, including a prior colonoscopy with significant findings (e.g. polyp with a positive finding, ulcerative colitis, Crohn's disease, inflammatory disease) Has a condition that precludes the safe performance of the submandibular gland procedure or may interfere with obtaining evaluable submandibular tissue biopsies, including any previous or active significant disease affecting the submandibular gland (e.g. inflammatory disease, infection, tumor)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson's Disease Patients were receiving bilateral STN stimulation for more than six months. 2. They were optimized on conventional HFS for control of tremors, rigidity and bradykinesia yet complained of freezing of gait. 3. Subjects had an ability to walk at least 10 meters independently during ON DBS condition  gait disorders perceived by patients as a direct consequence of STN stimulation and not the primary disease. 2. any change in the HFS DBS settings, three months prior to participation in the study. 3. complete inability to walk despite assistance while DBS ON. 4. Subjects responding to reprogramming of chronic DBS settings (report improvement of freezing). 5. Subjects could not tolerate prolonged OFF medication condition
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Tourette's Syndrome Tourette Syndrome Gilles de la Tourette Syndrome Tourette Disorder Age at least of 18 years (with potential exceptions) Diagnosis of TS based on the diagnostic of the Tourette Syndrome Classification Study Group A Yale Tic Global Severity Scale (YTGSS) > 35/50 for at least 12 months, with tic severity documented by a standardized videotape assessment Inadequate response to standard drug treatment or botulinum toxin  Diagnosis of secondary tic disorder, of heredodegenerative or neurometabolic diseases or history of toxic exposures or encephalitis Previous surgery for TS (with potential exceptions)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-100.0,  Parkinson Disease Parkinsonism Male or Female Age 18-100 years Referred for clinical DAT SPECT in Turku or Helsinki
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Dyskinesia, Medication-Induced Parkinson's Disease advanced idiopathic Parkinson's disease (Brain Bank criteria) optimal clinical response to dopaminergic medication (>30% UPDRS-III improvement) presence of clinically relevant levodopa-induced peak-dose dyskinesias in at least one upper limb  MRI-incompatible metal objects in the body (e.g. cardiac pacemakers) other main neuropsychiatric co-morbidity
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 21.0-999.0,  Hypertension • Treated or untreated stage I hypertension  Diabetes mellitus Renal impairment (serum creatinine > 1.4 mg/dL) Any heart diseases such as congestive heart failure, sustained arrhythmia, or coronary heart disease Chronic regular NSAID use Allergy to thiazide diuretics Gastro-esophageal reflux disease (GERD) requiring treatment with acid reducing agents or antacid more than once a week Esophageal-gastric ulcer or history of gastrointestinal bleeding Chronic diarrhea, vomiting Excessive sweating Unprovoked hypokalemia (serum K < 3.5 mmol/L) or hyperkalemia (serum K > 5.3 mmol/L)
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Parkinson Disease Essential Tremor Idiopathic Parkinson's Disease as defined by the UK brain bank and history of resting tremor, or Essential Tremor with history of resting tremor. Diagnosis made by a movement disorder specialist Midstage in disease process for Parkinson's disease with history of resting tremor  Dementia as defined by a mini-mental state examination cutoff score of 27 Atypical Parkinsonism Akinesia/ rigidity Parkinson's Disease Movement Disorders Stiff-Person syndrome, choreatic disease, dystonia, progressive supranuclear palsy Motor neuron disease Multiple sclerosis, amyotrophic lateral sclerosis, motor neuritis, progressive bulbar palsy, progressive muscular atrophy, spinal muscular atrophy Significant neurological comorbidities Stroke Brain cancer or brain metastases
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Depression Sedentary, i.e., have not participated regularly in moderate-to-vigorous physical activity (MVPA) for 90 minutes per week or more for the past 12 weeks. 2. Medically cleared for MVPA, documented by a note from their primary care provider. 3. No significant medical condition or physical disability that would interfere with physical activity or study participation. The investigators will individuals with significant cardiovascular disease, hematologic disorders, and autoimmune disorders. The investigators will also individuals who are planning a surgery in the next 9 months and those with dementia. 4. Elevated depression symptoms. To meet for elevated symptoms, participants must have a QIDS score of 10 or greater (i.e., at least moderate depression levels), and must have a score of "1" or greater on at least one of the two core DSM-V depressive symptoms, i.e., sad mood or anhedonia. - 5. No current bulimia or anorexia (past 3 months); no history of bipolar disorder, schizophrenia, or a chronic psychotic condition (assessed using the SCID). 6. No hazardous drug or alcohol use in the past 6 months, as assessed by: a. no substance abuse treatment in the past 6 months; and b. does not meet for a substance use disorder in the past 6 months. 7. Depression is not very severe, i.e., QIDS score is < 20. 8. No suicidality requiring immediate treatment. 9. Not pregnant or planning on becoming pregnant in the next year. 10. Understands English sufficiently well to consent and complete study assessments. 11. Aged 18-65. 12. Able to make one of the 2 available exercise class times. 13. Able to walk 1 mile
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Parkinson Disease-tremor Essential Tremor Patients with essential Tremor and unilateral tremor-dominant Idiopathic Parkinson's Disease -undergoing ExAblate 4000 Transcranial MR guided focused ultrasound (TcMRgFUS) thalamotomy)  In the investigator's opinion, any unstable or clinically significant condition that would impair the participants' ability to comply with study requirements Patients with significant psychiatric symptoms or history Treatment with neuroleptics Currently with lice or open wounds on scalp Significant sensory deficits, e.g., deafness or blindness Current drug abuse or alcoholism Pregnancy or not using a reliable method of birth control
Patient description: The patient is a 55-year-old man who was recently diagnosed with Parkinson's disease. He is complaining of slowness of movement and tremors. His disease is ranked as mild, Hoehn-Yahr Stage I. His past medical history is significant for hypertension and hypercholesterolemia. He lives with his wife. They have three children. He used to be active with gardening before his diagnosis. He complains of shaking and slow movement. He had difficulty entering through a door, as he was frozen and needed guidance to step in. His handwriting is getting smaller. He is offered Levodopa and Trihexyphenidyl. He is an alert and cooperative man who does not have any signs of dementia. He does not smoke or use any illicit drugs.

Clinical trial eligibility criteria: eligible ages (years): 20.0-80.0,  Obstructive Sleep Apnea Patients ranging from 20 years 2. Body mass index (BMI) of 20-38 to the typical obese OSA patients and avoid the practical difficulties in blood drawing from the massively obese 3. Hypertension with blood pressures > 140/90 but less than 180/105 mmHg. 4. Apnea-hypopnea index above 10  Receiving medications other than anti-hypertensives known to influence the sympathetic nervous system, sleep medicines (including heavy alcohol use) or drugs with adverse interactions with study medication. 2. Women who have premenstrual syndrome, or those who are pregnant or capable of pregnancy and unwilling to use effective non-hormonal contraception 3. Shift workers or have symptoms of narcolepsy, restless legs syndrome or insomnia, in order to minimize confounding effects of other sleep disorders 4. Have apneas which are primarily central 5. Have sleep fragmentation caused by syndromes such as chronic pain or movement disorders 6. Have diseases such as asthma or chronic obstructive pulmonary disease that compromises respiration. 7. Have known coronary or cerebral vascular disease, history of arrhythmias, cardiomyopathy, history of psychosis, current alcohol or drug abuse. 8. Have any contraindications to any study materials, such as heart block. 9. Have secondary hypertension 10. Have creatinine levels above 2.5 mg %, more than 1+ proteinuria by dipstick, hematuria or electrolyte disorders